In a significant stride towards addressing the challenge of Men-B disease, Serum Institute of India Pvt. Ltd (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation.
This partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine.
The agreement underscores the shared institutional commitment to combat disease caused by Neisseria meningitidis and represents a proactive response to overcome the limitations of currently available Men-B vaccines in terms of efficacy, safety, and coverage.
Read more on the Sir William Dunn School of Pathology website
The full story is also on the Oxford University Innovation website